623 results on '"Bo, X."'
Search Results
2. THE ADSORPTION CHARACTERISTICS OF SALT MODIFIED ZEOLITE TO AMMONIA NITROGEN.
- Author
-
BO, X., GUO, M.-X., LI, X.-C., WU, J.-J., LIU, S.-X., and WANG, C.-Y.
- Subjects
ZEOLITES ,SOLUTION (Chemistry) ,SODIUM tungstate ,AMMONIA ,NITROGEN in water ,NITROGEN - Abstract
To improve the adsorption capacity of natural zeolite for ammonia nitrogen, zeolite was modified by sodium chloride (NaCl), sodium tungstate (Na2WO4), and sodium citrate (C6H5Na3O7) solutions, and the adsorption characteristics of zeolite before and after modification for ammonia nitrogen in water were studied. The properties and structure of zeolite were characterized and analyzed. The adsorption mechanism of modified zeolite for ammonia nitrogen and the effects of environmental factors on the adsorption were studied. The results showed that the modification of NaCl, Na2WO4, and C6H5Na3O7 increased the adsorption capacity of zeolite by 60.76%, 58.23%, and 54.43%, respectively. The zeolite modified by NaCl solution had the best adsorption effect for ammonia nitrogen. The optimum concentration, temperature, and time of NaCl modifier was 1.5 mol/L, 85, and 12 h. The adsorption of ammonia nitrogen on zeolites before and after modification was more consistent with the pseudo-secondorder kinetic model. Under the conditions of particle size of 60-80 mesh, pH of 7, temperature of 30, and dosage of 10 g/L, the removal rate of ammonia nitrogen by zeolites increased from 54.89% to 90.39% after adsorption of wastewater with initial ammonia nitrogen concentration of 50 mg/L. The adsorption of ammonia nitrogen in wastewater by natural zeolite modified by salt solution is an environmentally friendly and effective method. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Potential therapeutic value of primary tumor resection in ampullary cancer patients with distant metastases at initial diagnosis: a population-based study
- Author
-
Wang J, Bo X, Lu P, Suo T, Ni X, Liu H, Pan H, Shen S, Li M, Zhang D, Wang Y, and Liu HB
- Subjects
ampullary cancer ,PSM ,primary tumor resection ,chemotherapy. ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Jie Wang,1,* Xiaobo Bo,1,* Pinxiang Lu,2,* Tao Suo,1 Xiaoling Ni,1 Han Liu,1 Hongtao Pan,1 Sheng Shen,1 Min Li,1 Dexiang Zhang,2 Yueqi Wang,1 Houbao Liu1 1Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; 2Department of General Surgery, Xuhui Central Hospital, Shanghai, China *These authors contributed equally to this work Objective: To evaluate the therapeutic value of primary tumor resection (PTR) in metastatic ampullary cancer at the initial presentation. Patients and methods: Patients with metastatic ampullary cancer were identified from Surveillance, Epidemiology and End Results database. Propensity score matching (PSM) was performed to balance the characteristics of our cohort. Kaplan–Meier analyses, log-rank tests and multivariate Cox regression models were employed to evaluate the therapeutic value of PTR. Results: A total of 346 patients with metastatic ampullary cancer were identified from 2004 to 2014 and 90 patients were screened by PSM. PTR was associated with favorable overall survival (OS) and cancer-specific survival (CSS) after PSM (PTR vs no-PTR: 16.0, 95% CI: 9.0–22.0 vs 8.0, 95% CI: 5.0–11.0 for median OS; 22.0, 95% CI: 13.0–33.0 vs 9.0, 95% CI: 5.0–11.0 for median CSS; both log-rank P
- Published
- 2018
4. Volatile organic compounds constituents of a typical integrated iron and steel plant and influence on O3 pollution.
- Author
-
Wang, Y., Zhu, R., Bo, X., Dan, M., and Shu, M.
- Subjects
STEEL mills ,VOLATILE organic compounds ,IRON ,AIR heaters ,COKE (Coal product) ,POLLUTION - Abstract
A typical integrated iron and steel plant in the Beijing–Tianjin–Hebei (BTH) of China was selected to measure volatile organic compound (VOC) constituents from five exhaust stacks belonging to the air heaters, coking, converters, heads, and tails of the sintering machines. The VOC source profiles were established based on the process, and the contribution of VOCs to ozone formation was analyzed in combination with the ozone formation potential (OFP). The concentration of total VOCs (TVOCs) emitted by different processes in the steel plant was 140.5–364.2 μg/m
3 . The sequence of TVOC concentrations was as follows: sinter-tail > coking ≈ sinter-head > converter > air heater. Alkanes and aromatic compounds were the predominant groups constituting 48.3% and 36.6% of the VOC concentration, respectively. However, the calculated results with OFP were different, and the contribution of aromatics reached a maximum of 59.8%, followed by alkanes (30.7%). The sequence of OFP for different processes was sinter-head > sinter-tail > coking > converter > air heater. The sinter-head became the segment that contributed the most to ozone formation in the plant; the reason was that the exhaust from sinter-head contained a large amount of aromatic species, which tend to have a greater maximum incremental reactivity (MIR) due to the difference in chemical reactivity. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
5. Two cytokine signaling molecules co-operate to promote axonal transport and growth
- Author
-
Miao, T., Wu, D., Wheeler, A., Wang, P., Zhang, Y., Bo, X., Yeh, J.S., Subang, M.C., and Richardson, P.M.
- Published
- 2011
- Full Text
- View/download PDF
6. ARQ-197 enhances the antitumor effect of sorafenib in hepatocellular carcinoma cells via decelerating its intracellular clearance
- Author
-
Gao X, Chen H, Huang X, Li H, Liu Z, and Bo X
- Subjects
drug clearance ,epithelial-mesenchymal transition ,multi-drug resistance ,molecular targeted agents ,advanced hepatocellular carcinoma ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,neoplasms ,lcsh:RC254-282 ,digestive system diseases ,ARQ-197 and sorafenib - Abstract
Xudong Gao,1,2 Hebing Chen,1 Xin Huang,1 Hao Li,1 Zhen Liu,1 Xiaochen Bo1 1Beijing Institute of Radiation Medicine, Beijing 100850, People’s Republic of China; 2The 5th Medical Center of PLA General Hospital, Beijing 100039, People’s Republic of China Background: Hepatocellular carcinoma (HCC) is one of the heaviest malignant burdens in China. Molecular targeting agent, sorafenib, is the main therapeutic option for antitumor therapy of advanced HCC, but it is currently too expensive for the public and its therapeutic effect does not satisfy initial expectation. Therefore, it is important to develop more effective molecular targeted therapeutic strategies for advanced HCC. Materials and methods: The antitumor effects of sorafenib or ARQ-197, an antagonist of c-MET (tyrosine-protein kinase Met or hepatocyte growth factor receptor), were examined by MTT or in murine tumor model. The effect of ARQ-197 on epithelial–mesenchymal transition (EMT) or multidrug resistance (MDR) was examined by quantitative real-time PCR for the expression of related genes. The clearance of sorafenib in HCC cells was detected by liquid chromatography-mass spectrometry/mass spectrometry. Results: ARQ-197 treatment enhanced the sensitivity of HCC cells to sorafenib. Mechanistic studies indicated that ARQ-197 inhibited the expression of EMT- and MDR-related genes. Moreover, ARQ-197 treatment decelerated the clearance of sorafenib in cultured HCC cells and subcutaneous HCC tumors in nude mice. Conclusion: In the present work, our data suggested that ARQ-197 decelerated the clearance of sorafenib in HCC cells and enhanced the antitumor effect of sorafenib. Keywords: advanced hepatocellular carcinoma, molecular targeted agents, ARQ-197 and sorafenib, drug clearance, epithelial–mesenchymal transition, multidrug resistance
- Published
- 2019
7. Evolution mechanism of compression deformation of carbon black reinforced epoxy resin composites.
- Author
-
Wu, Z., Jang, H.F., Bo, X., Yang, C.M., Zhang, Y., and Wan, J.Q.
- Subjects
CARBON-black ,EPOXY resins ,RUBBER powders ,SCANNING electron microscopes ,POWDERS ,REINFORCEMENT of rubber - Abstract
In this paper, the double‐element composites were developed, which contained the epoxy resin as matrix phase and carbon black rubber powder as toughening materials. Quasi‐static compression tests on epoxy resin and different mass fractions carbon black rubber powder‐epoxy resin composites were performed in room temperature to test their compression properties. The energy absorption performance and the energy absorption efficiency of the composites were calculated according to the compression curve. The fracture characteristics of the micro appearance of the compressed material specimen were observed by scanning electron microscope. The deformation mode of the composite was analyzed. By systematically analyzing the effects of carbon black rubber powder content on the mechanical properties of carbon black rubber powder‐epoxy resin, it was found that carbon black rubber powder as a reinforced material could effectively improve the brittleness of epoxy resin, the yield strength and the adsorption properties and efficiency of composites. With the mass fraction of carbon black rubber powder increasing, the energy absorption performance of carbon black rubber powder‐epoxy resin first increases and then decreases. The most significant performance observed was at a mass fraction of 5 % in carbon black rubber powder‐epoxy resin composites. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. A high-power long lifetime beam dump for the Thomson scattering diagnostic system in the XuanLong-50 experiment.
- Author
-
Liu, J. H., Li, S. J., Li, H. Y., Xie, Q. F., Bai, R. H., Bo, X. K., and Deng, B. H.
- Subjects
THOMSON scattering ,ELECTRON distribution ,LASER pulses ,PULSED lasers ,LASER beams ,BLOOD volume - Abstract
The Energy iNNovation's XuanLong-50 is a spherical torus experiment with up to 10 s plasma operation duration. A 3 J/50 Hz pulsed laser is used in the Thomson scattering diagnostic system that is developed to measure the time evolutions of plasma electron temperature and density profiles. The expected laser pulse number is about 7.5 × 10
6 /year with a power load of 150 W. To meet at least 1-year lifetime requirement, a Chevron type beam dump with polished molybdenum plates is designed and fabricated, which absorbs the laser beam energy in a 3D structure to reduce the laser fluence deposited on the material surface. To prevent the backscattered stray light from interfering with the Thomson scattering measurements, a 7.5 m beam path with folding mirrors is set between the beam dump and the plasma scattering volumes. Details of the beam dump design procedure including the laser beam profile control, multi-pulse laser damage threshold, heat dissipation, Zemax modeling, folding mirror selection, and beam path enclosure are presented together with the testing results. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
9. P-124 SHP-2 deficiency in myeloid cells promotes metastasis of esophageal carcinoma via increasing cathepsins and inflammatory factor secretion
- Author
-
Li, Q., Min, X., Tang, K., Bai, J., Bo, X., and Guo, P.
- Published
- 2023
- Full Text
- View/download PDF
10. Effect of annealing on electrical properties of radio-frequency-sputtered ZnO films
- Author
-
Alivov, Y. I., Bo, X., Akarca-Biyikli, S., Fan, Q., Xie, J., Biyikli, N., Zhu, K., Johnstone, D., and Morkoç, H.
- Published
- 2006
- Full Text
- View/download PDF
11. Double-antigen sandwich ELISA for detection of antibodies to SARS-associated coronavirus in human serum
- Author
-
Chen, S., Lu, D., Zhang, M., Che, J., Yin, Z., Zhang, S., Zhang, W., Bo, X., Ding, Y., and Wang, S.
- Published
- 2005
- Full Text
- View/download PDF
12. Thomson scattering diagnostic system for the XuanLong-50 experiment.
- Author
-
Li, H. Y., Li, S. J., Xie, Q. F., Liu, J. H., Bai, R. H., Tao, R. Y., Lun, X. C., Li, N., Bo, X. K., Liu, C. Q., Han, L., and Deng, B. H.
- Subjects
THOMSON scattering ,LIGHT transmission ,SIGNAL-to-noise ratio ,TORUS - Abstract
A 15-point Thomson scattering diagnostic system is developed for ENN's spherical torus experiment XuanLong-50 (EXL-50). A BeamTech laser with 3 J/pulse (1064 nm wavelength) at 50 Hz repetition rate is chosen for measurements during EXL-50 plasma operations. To enable measurements at low density (∼0.5 × 10
18 m−3 ) plasma operations, the opto-mechanical subsystems are carefully designed to maximize the collection and transmission of the scattered light and to minimize the stray light level. In addition, the high bandwidth trans-impedance amplifiers and segmented high speed waveform digitizers allow for the application of muti-pulse averaging to further improve the signal-to-noise ratio. Details of the diagnostic system are described and initial experimental results are presented. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
13. Incidence of Atrial Fibrillation after Lung Transplantation in 50 Cases
- Author
-
Yang, J, Wu, X Q, Chen, J Y, Zhen, M F, Bo, X P, and Lu, W H
- Published
- 2010
14. The pick-up stick transistor
- Author
-
Blanchet, Graciela B., Bo, X.-Z., Lee, C.Y., Strano, M.S., and Nuckolls, C.
- Published
- 2005
- Full Text
- View/download PDF
15. Antisense oligonucleotides targeted against asialoglycoprotein receptor 1 block human hepatitis B virus replication
- Author
-
Yang, J., Bo, X. C., Ding, X. R., Dai, J. M., Zhang, M. L., Wang, X. H., and Wang, S. Q.
- Published
- 2006
16. Differentially expressed cellular genes following HBV: potential targets of anti-HBV drugs?
- Author
-
Yang, J., Bo, X. C., Yao, J., Yang, N. M., and Wang, S. Q.
- Published
- 2005
17. A numerical study of hollow water drop breakup during freezing.
- Author
-
Vu, Truong V., Pham, Binh D., Pham, Phuc H., Vu, Hung V., and Tran, Bo X.
- Subjects
FREEZING ,CURVED surfaces ,PHASE diagrams - Abstract
We present a numerical investigation of the breakup and freezing of a pendant hollow water drop beneath a cold curved surface. The drop contains a bubble surrounded by a shell of water that forms at an outer wetting angle of θ
o with the surface. The freezing begins on the cold curved surface and evolves in the direction of gravity. As it freezes, the water accumulates and forms a bulbous end at the bottom of the drop. Breakup can occur, inducing a daughter water drop. As a result, the freezing process of the remaining hollow drop attached to the surface takes less time, and the frozen drop shrinks. However, this breakup has no effect on the bubble. The various parameters under consideration include the Bond number Bo, the Stefan number St, the size of the bubble, and the angle θo . It is found that the breakup of the drop during freezing takes place for increasing Bo (from 0.1 to 3.0), increasing θo (from 60° to 120°), decreasing St (in the range of 0.01–0.64), or decreasing bubble size. On the other hand, the shape of the curved surface has little influence on the breakup of the drop. Phase diagrams of θo vs Bo and of St vs Bo are also presented to provide a more general picture of the breakup and freezing of the water drop. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
18. Tumour necrosis factor α impairs function of liver derived T lymphocytes and natural killer cells in patients with primary sclerosing cholangitis
- Author
-
Bo, X, Broome, U, Remberger, M, and Sumitran-Holgersson, S
- Published
- 2001
19. Locally maximal idempotent-generated subsemigroups of singular orientation-preserving transformation semigroups
- Author
-
Zhao, P., Bo, X., and Mei, Y.
- Published
- 2008
- Full Text
- View/download PDF
20. Chapter 7 - Wearable Carbon Nanotube Devices for Sensing
- Author
-
Shen, H., Liu, T., Qin, D., Bo, X., Wang, L., Wang, F., Yuan, Q., Wagberg, T., Hu, G., and Zhou, M.
- Published
- 2017
- Full Text
- View/download PDF
21. The Surgical Treatment of Three Young Chronic Subdural Hematoma Patients with Different Causes
- Author
-
Kun Hou, Bo X Zhu, Yang Zhang, and Chen G Li
- Subjects
medicine.medical_specialty ,business.industry ,General Neuroscience ,Case Report ,Disease ,Chronic subdural hematoma ,medicine.disease ,Insidious onset ,Surgery ,Arachnoid cyst ,Young adult ,Cerebrospinal fluid leakage ,medicine ,Neurology (clinical) ,Risk factor ,Surgical treatment ,Intracranial Hypotension ,business ,Intracranial hypotension - Abstract
Chronic subdural hematoma (CSDH), which rarely happens in the young, is thought to be a disease of the elderly. Whereas unspecific symptoms and insidious onset in juveniles and young adults, as a result of its relative low morbidity, CSDH is usually neglected even undertreated in the young. Through the three cases and review of the current literature on this subject, we tried to illustrate the clinical and etiopathological characteristics of this entity and find out the most appropriate treatment strategy. We report three young CSDH patients with different but similar symptoms. The present histories, tests and examinations revealed different predisposing factors accounting for the genesis of CSDH. Their preoperative symptoms were all resolved with burr hole and drainage operation. Juveniles and young adults suffering from CSDH differ from that of their elderly counterparts in their clinical and etiopathological characteristics. Although trauma is the most important risk factor in young and old CSDH patients, some other predisposing factors may exist. Burr hole and drainage surgery could resolve the problem most of the time. But further tests and examinations even specific management should be made in some cases.
- Published
- 2014
22. In-plane optical anisotropy induced by asymmetrically δ-doping in (001) GaAs/AlGaAs quantum wells studied by reflectance difference spectroscopy.
- Author
-
Yu, J. L., Chen, Y. H., Bo, X., Jiang, C. Y., Ye, X. L., Wu, S. J., and Gao, H. S.
- Subjects
ANISOTROPY ,QUANTUM wells ,REFLECTANCE spectroscopy ,EXTRAPOLATION ,SEMICONDUCTOR doping - Abstract
In-plane optical anisotropy (IPOA) in modulation-doped (001) GaAs/AlGaAs quantum wells (QWs) has been studied by reflectance difference spectroscopy (RDS). By changing the position of the δ-doping layer, we introduce an asymmetric potential into the quantum well system, which results in an additional IPOA. Compared to symmetrically doped and undoped structure, the asymmetrically doped QWs exhibit larger IPOA, which is clearly demonstrated both by the RDS results measured at 80 K and the linear extrapolation of the RDS signal under uniaxial strain measured at room temperature. Numerical calculations within the envelope function framework show that the asymmetric potential induced by asymmetrically doping will introduce additional hole-mixing coefficients. This work demonstrates that the IPOA of QWs can be tailored by changing the delta-doping position. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
23. MiR-126 on mice with coronary artery disease by targeting S1PR2.
- Author
-
FAN, J.-L., ZHANG, L., and BO, X.-H.
- Abstract
OBJECTIVE: To screen the differentially expressed micro ribonucleic acids (miRNAs) in the serum of coronary atherosclerosis patients, and to investigate their possible mechanisms of action. PATIENTS AND METHODS: The differentially expressed serum miRNAs were screened from 3 coronary artery disease (CAD) patients and 3 healthy controls using miRNA expression profiles, which were verified using low-throughput quantitative Reverse Transcription-Polymerase Chain Reaction (RT-qPCR) assay. 60 apolipoprotein E (ApoE)-/- mice were divided into model group, agomir-126 group, agomir-control (con) group, and antagomir-126 group using a random number table. They were fed with high-fat diets (21% fat and 0.15% cholesterol) ad libitum for 15 weeks to establish the mouse model of CAD. Then, hematoxylin and eosin (HE) staining was applied to detect the impact of miR-126 expression level on the tissue morphology in the thoracic aortic region. The influences of miR-126 expression level on the secretion levels of tumor necrosis factor-alpha (TNF-a), interleukin-1 beta (IL-1ß), and IL-10 were determined via enzyme-linked immunosorbent assay (ELISA). Western blotting assay was performed to examine the effects of miR-126 expression level on the expression levels of nuclear factor-kappa B (NF-κB) and vascular cell adhesion molecule-1 (VACM-1) in the tissues of the thoracic aortic region of the mice. The correlation between miR-126 expression level and sphingosine-1-phosphate receptor 2 (S1PR2) in the serum of CAD patients and animal models was analyzed by the Pearson correlation coefficient method. The targets of miR-126 were predicted using the bioinformatics method, and the direct targets were verified through investigations. Western blotting assay and ELISA were adopted to detect the impacts of miR-126 expression level on the expression and secretion levels of TNF-a, IL-1ß, and IL-10 in S1P + oxidized low-density lipoprotein (ox-LDL)-induced human umbilical vein endothelial cells (HUVECs). Lentivirus-small hairpin RNA (shRNA) was utilized to knock down the expression level of S1RP2 to determine whether miR-126 affected the increase in the inflammation level in S1P + ox-LDL-induced HUVECs by targeting S1RP2. RESULTS: Compared with those in control group, 4 miRNAs (miR-126, miR-206, miR-4297, and miR-3646) in the serum of CAD patients exhibited the most significant expression differences, which increased by 6.72, 7.11, 13.57, and 21.22 times, respectively. The verification results of low-throughput RT-qPCR assay indicated that there were remarkable changes in the expression levels of the 4 selected miRNAs with differential expressions in comparison with those in control group, displaying statistically significant differences (p<0.01). The results of HE staining manifested that the coronary atherosclerotic plaques were reduced markedly in agomir-126 group, while notably more coronary atherosclerotic plaques were formed in the thoracic aortic region in antagomir-126 group. Meanwhile, the elevated expression level of miR-126 evidently lowered the expressions of serum TNF-a and IL-1ß, but significantly increased the expression of IL-10 in the mouse model of CAD. According to the analysis results of the Pearson correlation coefficient method, the miR-126 expression level was negatively correlated with S1PR2 expression level in the serum of both CAD patients and animal models (r=-0.6123, r=-5.37). It was shown in bioinformatics prediction and luciferase reporter gene assay that miR-126 negatively regulated the S1PR2 expression by targeting the 3' untranslated region (UTR) of S1PR2 messenger RNA (mRNA). In the in vitro inflammation model, the increased expression level of miR-126 could relieve the inflammation in cells induced by S1P + ox-LDL. Based on the results of both Western blotting assay and ELISA, the differences in the expression and secretion levels of TNF-a, IL-1ß, and IL-10, as well as the expression levels of signaling molecules of the NF-κB signaling pathway, in the cells were not statistically significant among miR-126 mimic treatment group, sh-S1PR2 group, and miR-126 mimic + sh-S1PR2 group, indicating that miR-126 affects the inflammation level in HUVECs by targeting S1PR2. CONCLUSIONS: MiR-126 represses the progression of coronary atherosclerosis in the mice by binding to S1PR2. The results of this research may propose a new mechanism of miR-126 in exerting its therapeutic effects and possess potential value for the treatment of CAD in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2020
24. Production of charged pions, kaons and protons at large transverse momenta in pp and Pb–Pb collisions at √sNN = 2.76 TeV
- Author
-
Piano, Stefano, Lea, Ramona, Camerini, Paolo, Luparello, Grazia, Margagliotti, Giacomo, Rui, Rinaldo, Abelev bt, B., Adam ak, J., Adamová cb, D., Aggarwal cf, M. M., Aglieri Rinella ah, G., Agnello cm, M., Agostinelli z, A., Agrawal ar, N., Ahammed dw, Z., Ahmad r, N., Ahmad Masoodi r, A., Ahmed o, I., Ahn bm, S. U., Ahn bm, S. A., Aimo cm, I., Aiola eb, S., Ajaz o, M., Akindinov bc, A., Aleksandrov cs, D., Alessandro dd, B., Alexandre cu, D., Alici cx, A., L, Alkin c, A., Alme ai, J., Alt am, T., Altini ae, V., Altinpinar q, S., Altsybeev dv, I., Alves Garcia Prado dl, C., Andrei bw, C., Andronic cp, A., Anguelov cl, V., Anielski ay, J., Anticˇic ́ cq, T., Antinori da, F., Antonioli cx, P., Aphecetche df, L., Appelshäuser aw, H., Arbor bp, N., Arcelli z, S., Armesto p, N., Arnaldi dd, R., Aronsson eb, T., Arsene u, I. C., Arslandok aw, M., Augustinus ah, A., Averbeck cp, R., Awes cc, T. C., Azmi r, M. D., Bach am, M., Badalà cz, A., Baek an, Y. W., Bagnasco dd, S., Bailhache aw, R., Bairathi cj, V., Bala ci, R., Baldisseri n, A., Baltasar Dos Santos Pedrosa ah, F., Bán bd, J., Baral bf, R. C., Barbera aa, R., Barile ae, F., Barnaföldi ea, G. G., Barnby cu, L. S., Barret bo, V., Bartke di, J., Basile z, M., Bastid bo, N., Basu dw, S., Bathen ay, B., Batigne df, G., Batyunya bk, B., Batzing u, P. C., Baumann aw, C., Bearden by, I. G., Beck aw, H., Bedda cm, C., Behera ar, N. K., Belikov az, I., Bellini z, F., Bellwied dn, R., Belmont Moreno bi, E., Bencedi ea, G., Beole y, S., Berceanu bw, I., Bercuci bw, A., Berdnikov cd, Y., 1, Berenyi ea, D., Berger ck, M. E., Bertens bb, R. A., Berzano y, D., Betev ah, L., Bhasin ci, A., Bhati cf, A. K., Bhattacharjee ao, B., Bhom ds, J., Bianchi y, L., Bianchi bq, N., Bianchin bb, C., Bielcˇík ak, J., Bielcˇíková cb, J., Bilandzic by, A., Bjelogrlic bb, S., Blanco j, F., Blau cs, D., Blume aw, C., Bock cl, F., Bogdanov bu, A., Bøggild by, H., Bogolyubsky de, M., Böhmer ck, F. V., Boldizsár ea, L., Bombara al, M., Book aw, J., Borel n, H., Borissov dz, A., Bornschein am, J., Bossú bj, F., Botje bz, M., Botta y, E., Böttger av, S., Braun Munzinger cp, P., Bregant dl, M., Breitner av, T., Broker aw, T. A., Browning cn, T. A., Broz aj, M., Bruna dd, E., Bruno ae, G. E., Budnikov cr, D., Buesching aw, H., Bufalino dd, S., Buncic ah, P., Busch cl, O., Buthelezi bj, Z., Caffarri ab, D., Cai g, X., Caines eb, H., Caliva bb, A., Calvo Villar cv, E., Canoa Roman ah, V., Carena ah, F., Carena ah, W., Carminati ah, F., Casanova Díaz bq, A., Castillo Castellanos n, J., Casula w, E. A. R., Catanescu bw, V., Cavicchioli ah, C., Ceballos Sanchez i, C., Cepila ak, J., Cerello dd, P., Chang do, B., Chapeland ah, S., Charvet n, J. L., Chattopadhyay dw, S., Chattopadhyay ct, S., Cherney ce, M., Cheshkov du, C., Cheynis du, B., Chibante Barroso ah, V., Chinellato dn, D. D., Chochula ah, P., Chojnacki by, M., Choudhury dw, S., Christakoglou bz, P., Christensen by, C. H., Christiansen af, P., Chujo ds, T., Chung co, S. U., Cicalo cy, C., Cifarelli l, L., Z, Cindolo cx, F., Cleymans ch, J., Colamaria ae, F., Colella ae, D., Collu w, A., Colocci z, M., Conesa Balbastre bp, G., Conesa del Valle au, Z., Connors eb, M. E., Contin x, G., Contreras k, J. G., Cormier cc, T. M., Corrales Morales y, Y., Cortese ad, P., Cortés Maldonado b, I., Cosentino bs, M. R., Costa ah, F., Crochet bo, P., Cruz Albino k, R., Cuautle bh, E., Cunqueiro bq, L., Dainese da, A., Dang g, R., Danu bg, A., Das ct, D., Das au, I., Das ct, K., Das d, S., Dash dm, A., Dash ar, S., De dw, S., Delagrange df, H., 2, Deloff bv, A., Dénes ea, E., D’Erasmo ae, G., de Barros dl, G. O. V., De Caro l, A., de Cataldo cw, G., de Cuveland am, J., De Falco w, A., De Gruttola ac, D., De Marco dd, N., De Pasquale ac, S., de Rooij bb, R., Diaz Corchero j, M. A., Dietel ay, T., Divià ah, R., Di Bari ae, D., Di Liberto db, S., Di Mauro ah, A., Di Nezza bq, P., Djuvsland q, Ø., Dobrin bb, A., Dobrowolski bv, T., Domenicis Gimenez dl, D., Dönigus aw, B., Dordic u, O., Dørheim ck, S., Dubey dw, A. K., Dubla bb, A., Ducroux du, L., Dupieux bo, P., Dutta Majumdar ct, A. K., Ehlers eb, R. J., Elia cw, D., Engel av, H., Erazmus ah, B., Erdal ai, H. A., Eschweiler am, D., Espagnon au, B., Estienne df, M., Esumi ds, S., Evans cu, D., Evdokimov de, S., Eyyubova u, G., Fabris da, D., Faivre bp, J., Falchieri z, D., Fantoni bq, A., Fasel cl, M., Fehlker q, D., Feldkamp ay, L., Felea bg, D., Feliciello dd, A., Feofilov dv, G., Ferencei cb, J., Fernández Téllez b, A., Ferreiro p, E. G., Ferretti y, A., Festanti ab, A., Figiel di, J., Figueredo dl, M. A. S., Filchagin cr, S., Finogeev ba, D., Fionda ae, F. M., Fiore ae, E. M., Floratos cg, E., Floris ah, M., Foertsch bj, S., Foka cp, P., Fokin cs, S., Fragiacomo dc, E., Francescon ab, A., Frankenfeld cp, U., Fuchs ah, U., Furget bp, C., Fusco Girard ac, M., Gaardhøje by, J. J., Gagliardi y, M., Gago cv, A. M., Gallio y, M., Gangadharan s, D. R., Ganoti cg, P., Garabatos cp, C., Garcia Solis m, E., Gargiulo ah, C., Garishvili bt, I., Gerhard am, J., Germain df, M., Gheata ah, A., Gheata bg, M., Ghidini ae, B., Ghosh dw, P., Ghosh d, S. K., Gianotti bq, P., Giubellino ah, P., Gladysz Dziadus di, E., Glässel cl, P., Gomez k, R., González Zamora j, P., Gorbunov am, S., Görlich di, L., Gotovac dh, S., Graczykowski dy, L. K., Grajcarek cl, R., Grelli bb, A., Grigoras ah, A., Grigoras ah, C., Grigoriev bu, V., Grigoryan a, A., Grigoryan bk, S., Grinyov c, B., Grion dc, N., Grosse Oetringhaus ah, J. F., Grossiord du, J. Y., Grosso ah, R., Guber ba, F., Guernane bp, R., Guerzoni z, B., Guilbaud du, M., Gulbrandsen by, K., Gulkanyan a, H., Gunji dr, T., Gupta ci, A., Gupta ci, R., Khan o, K. H., Haake ay, R., Haaland q, Ø., Hadjidakis au, C., Haiduc bg, M., Hamagaki dr, H., Hamar ea, G., Hanratty cu, L. D., Hansen by, A., Harris eb, J. W., Hartmann am, H., Harton m, A., Hatzifotiadou cx, D., Hayashi dr, S., Heckel aw, S. T., Heide ay, M., Helstrup ai, H., Herghelegiu bw, A., Herrera Corral k, G., Hess ag, B. A., Hetland ai, K. F., Hicks eb, B., Hippolyte az, B., Hladky be, J., Hristov ah, P., Huang q, M., Humanic s, T. J., Hutter am, D., Hwang t, D. S., Ilkaev cr, R., Ilkiv bv, I., Inaba ds, M., Incani w, E., Innocenti y, G. M., Ionita ah, C., Ippolitov cs, M., Irfan r, M., Ivanov cp, M., Ivanov cd, V., Ivanytskyi c, O., Jachołkowski aa, A., Jacobs bs, P. M., Jahnke dl, C., Jang bm, H. J., Janik dy, M. A., Jayarathna dn, P. H. S. Y., Jena ar, S., Jimenez Bustamante bh, R. T., Jones cu, P. G., Jung an, H., Jusko cu, A., Kalcher am, S., Kalinak bd, P., Kalweit ah, A., Kamin aw, J., Kang ec, J. H., Kaplin bu, V., Kar dw, S., Karasu Uysal bn, A., Karavichev ba, O., Karavicheva ba, T., Karpechev ba, E., Kebschull av, U., Keidel ed, R., Ketzer ck, B., Khan r, M. M., 3, Khan ct, P., Khan dw, S. A., Khanzadeev cd, A., Kharlov de, Y., Kileng ai, B., Kim ec, B., Kim bm, D. W., Kim do, D. J., Kim an, J. S., Kim an, M., Kim ec, M., Kim t, S., Kim ec, T., Kirsch am, S., Kisel am, I., Kiselev bc, S., Kisiel dy, A., Kiss ea, G., Klay f, J. L., Klein cl, J., Klein Bösing ay, C., Kluge ah, A., Knichel cp, M. L., Knospe dj, A. G., Kobdaj ah, C., Kofarago ah, M., Köhler cp, M. K., Kollegger am, T., Kolojvari dv, A., Kondratiev dv, V., Kondratyeva bu, N., Konevskikh ba, A., Kovalenko dv, V., Kowalski ah, M., Kox bp, S., Koyithatta Meethaleveedu ar, G., Kral do, J., Králik bd, I., Kramer aw, F., Kravcˇáková al, A., Krelina ak, M., Kretz am, M., Krivda cu, M., Krizek cb, F., Krus ak, M., Kryshen cd, E., Krzewicki cp, M., Kucˇera cb, V., Kucheriaev cs, Y., Kugathasan ah, T., Kuhn az, C., Kuijer bz, P. G., Kulakov aw, I., Kumar ar, J., Kurashvili bv, P., Kurepin ba, A., Kurepin ba, A. B., Kuryakin cr, A., Kushpil cb, S., Kushpil cb, V., Kweon cl, M. J., Kwon ec, Y., Ladron de Guevara bh, P., Lagana Fernandes dl, C., Lakomov au, I., Langoy dx, R., Lara av, C., Lardeux df, A., Lattuca y, A., La Pointe dd, S. L., La Rocca aa, P., Leardini cl, L., Lee cu, G. R., Legrand ah, I., Lehnert aw, J., Lemmon ca, R. C., Lenhardt cp, M., Lenti cw, V., Leogrande bb, E., Leoncino y, M., León Monzón dk, I., Lévai ea, P., Li g, S., Lien dx, J., Lietava cu, R., Lindal u, S., Lindenstruth am, V., Lippmann cp, C., Lisa s, M. A., Ljunggren af, H. M., Lodato bb, D. F., Loenne q, P. I., Loggins dz, V. R., Loginov bu, V., Lohner cl, D., Loizides bs, C., Lopez bo, X., López Torres i, E., Lu cl, X. G., Luettig aw, P., Lunardon ab, M., Luo g, J., Luzzi ah, C., Ma eb, R., Maevskaya ba, A., Mager ah, M., Mahapatra bf, D. P., Maire cl, A., Malaev cd, M., Maldonado Cervantes bh, I., Malinina bk, L., 4, Mal’Kevich bc, D., Malzacher cp, P., Mamonov cr, A., Manceau dd, L., Manko cs, V., Manso bo, F., Manzari ah, V., Marchisone y, M., Mareš be, J., Margotti cx, A., Marín cp, A., Markert ah, C., Marquard aw, M., Martashvili dq, I., Martin cp, N. A., Martinengo ah, P., Martínez b, M. I., Martínez García df, G., Martin Blanco df, J., Martynov c, Y., Mas df, A., Masciocchi cp, S., Masera y, M., Masoni cy, A., Massacrier df, L., Mastroserio ae, A., Matyja di, A., Mayer di, C., Mazer dq, J., Mazumder as, R., Mazzoni db, M. A., Meddi v, F., Menchaca Rocha bi, A., Meninno ac, E., Mercado Pérez cl, J., Meres aj, M., Miake ds, Y., Mikhaylov bc, K., Milano ah, L., Milosevic u, J., 5, Mischke bb, A., Mishra as, A. N., Mis ́kowiec cp, D., Mitu bg, C. M., Mlynarz dz, J., Mohanty dw, B., Molnar az, L., Montaño Zetina k, L., Montes j, E., Morando ab, M., Moreira De Godoy dl, D. A., Moretto ab, S., Morreale do, A., Morsch ah, A., Muccifora bq, V., Mudnic dh, E., Muhuri dw, S., Mukherjee dw, M., Müller ah, H., Munhoz dl, M. G., Murray ch, S., Musa ah, L., Musinsky bd, J., Nandi ar, B. K., Nania cx, R., Nappi cw, E., Nattrass dq, C., Nayak dw, T. K., Nazarenko cr, S., Nedosekin bc, A., Nicassio cp, M., Niculescu bg, M., Nielsen by, B. S., Nikolaev cs, S., Nikulin cs, S., Nikulin cd, V., Nilsen ce, B. S., Noferini l, F., Nomokonov bk, P., Nooren bb, G., Nyanin cs, A., Nystrand q, J., Oeschler cl, H., Oh eb, S., Oh bl, S. K., An, 6, Okatan bn, A., Olah ea, L., Oleniacz dy, J., Oliveira Da Silva dl, A. C., Onderwaater cp, J., Oppedisano dd, C., Ortiz Velasquez af, A., Oskarsson af, A., Otwinowski cp, J., Oyama cl, K., Pachmayer cl, Y., Pachr ak, M., Pagano ac, P., Paic ́ bh, G., Painke am, F., Pajares p, C., Pal dw, S. K., Palmeri cz, A., Pant ar, D., Papikyan a, V., Pappalardo cz, G. S., Park cp, W. J., Passfeld ay, A., Patalakha de, D. I., Paticchio cw, V., Paul ct, B., Pawlak dy, T., Peitzmann bb, T., Pereira Da Costa n, H., Pereira De Oliveira Filho dl, E., Peresunko cs, D., Pérez Lara bz, C. E., Peryt dy, W., Pesci cx, A., Pestov e, Y., Petrácˇek ak, V., Petran ak, M., Petris bw, M., Petrovici bw, M., Petta aa, C., Pikna aj, M., Pillot df, P., Pinazza ah, O., Pinsky dn, L., Piyarathna dn, D. B., Płoskon ́ bs, M., Planinic cq, M., Pluta dy, J., Pochybova ea, S., Podesta Lerma dk, P. L. M., Poghosyan ah, M. G., Pohjoisaho ap, E. H. O., Polichtchouk de, B., Poljak cq, N., Pop bw, A., Porteboeuf Houssais bo, S., Porter bs, J., Pospisil ak, V., Potukuchi ci, B., Prasad d, S. K., Preghenella cx, R., Prino dd, F., Pruneau dz, C. A., Pshenichnov ba, I., Puddu w, G., Punin cr, V., Putschke dz, J., Qvigstad u, H., Rachevski dc, A., Raha d, S., Rak do, J., Rakotozafindrabe n, A., Ramello ad, L., Raniwala cj, R., Raniwala cj, S., Räsänen ap, S. S., Rascanu aw, B. T., Rathee cf, D., Rauf o, A. W., Razazi w, V., Read dq, K. F., Real bp, J. S., Redlich bv, K., 7, Reed eb, R. J., Rehman q, A., Reichelt aw, P., Reicher bb, M., Reidt cl, F., Renfordt aw, R., Reolon bq, A. R., Reshetin ba, A., Rettig am, F., Revol ah, J. P., Reygers cl, K., Riabov cd, V., Ricci br, R. A., Richert af, T., Richter u, M., Riedler ah, P., Riegler ah, W., Riggi aa, F., Rivetti dd, A., Rocco bb, E., Rodríguez Cahuantzi b, M., Rodriguez Manso bz, A., Røed u, K., Rogochaya bk, E., Rohni ci, S., Rohr am, D., Röhrich q, D., Romita dp, R., Ronchetti bq, F., Ronflette df, L., Rosnet bo, P., Rossegger ah, S., Rossi ah, A., Roukoutakis cg, F., Roy as, A., Roy az, C., Roy ct, P., Rubio Montero j, A. J., Russo y, R., Ryabinkin cs, E., Ryabov cd, Y., Rybicki di, A., Sadovsky de, S., Šafarˇík ah, K., Sahlmuller aw, B., Sahoo as, R., Sahu bf, P. K., Saini dw, J., Salgado p, C. A., Salzwedel s, J., Sambyal ci, S., Samsonov cd, V., Sanchez Castro az, X., Sánchez Rodríguez dk, F. J., Šándor bd, L., Sandoval bi, A., Sano ds, M., Santagati aa, G., Sarkar dw, D., Scapparone cx, E., Scarlassara ab, F., Scharenberg cn, R. P., Schiaua bw, C., Schicker cl, R., Schmidt cp, C., Schmidt ag, H. R., Schuchmann aw, S., Schukraft ah, J., Schulc ak, M., Schuster eb, T., Schutz ah, Y., Schwarz cp, K., Schweda cp, K., Scioli z, G., Scomparin dd, E., Scott cu, P. A., Scott dq, R., Segato ab, G., Seger ce, J. E., Selyuzhenkov cp, I., Seo co, J., Serradilla j, E., Sevcenco bg, A., Shabetai df, A., Shabratova bk, G., Shahoyan ah, R., Shangaraev de, A., Sharma dq, N., Sharma ci, S., Shigaki aq, K., Shtejer y, K., Sibiriak cs, Y., Siddhanta cy, S., Siemiarczuk bv, T., Silvermyr cc, D., Silvestre bp, C., Simatovic dt, G., Singaraju dw, R., Singh ci, R., Singha bx, S., Singhal dw, V., Sinha dw, B. C., Sinha ct, T., Sitar aj, B., Sitta ad, M., Skaali u, T. B., Skjerdal q, K., Smakal ak, R., Smirnov eb, N., Snellings bb, R. J. M., Søgaard af, C., Soltz bt, R., Song co, J., Song ec, M., Soramel ab, F., Sorensen dq, S., Spacek ak, M., Sputowska di, I., Spyropoulou Stassinaki cg, M., Srivastava cn, B. K., Stachel cl, J., Stan bg, I., Stefanek bv, G., Steinpreis s, M., Stenlund af, E., Steyn bj, G., Stiller cl, J. H., Stocco df, D., Stolpovskiy de, M., Strmen aj, P., Suaide dl, A. A. P., Subieta Vasquez y, M. A., Sugitate aq, T., Suire au, C., Suleymanov o, M., Sultanov bc, R., Šumbera cb, M., Susa cq, T., Symons bs, T. J. M., Szanto de Toledo dl, A., Szarka aj, I., Szczepankiewicz ah, A., Szymanski dy, M., Takahashi dm, J., Tangaro ae, M. A., Tapia Takaki au, J. D., 8, Tarantola Peloni aw, A., Tarazona Martinez ah, A., Tarzila bw, M. G., Tauro ah, A., Tejeda Muñoz b, G., Telesca ah, A., Terrevoli w, C., Ter Minasyan bu, A., Thäder cp, J., Thomas bb, D., Tieulent du, R., Timmins dn, A. R., Toia da, A., Torii dr, H., Trubnikov c, V., Trzaska do, W. H., Tsuji dr, T., Tumkin cr, A., Turrisi da, R., Tveter u, T. S., Ulery aw, J., Ullaland q, K., Uras du, A., Usai w, G. L., Vajzer cb, M., Vala bk, M., Valencia Palomo au, L., Vallero y, S., Vande Vyvre ah, P., Vannucci br, L., Van Der Maarel bb, J., Van Hoorne ah, J. W., van Leeuwen bb, M., Vargas b, A., Varma ar, R., Vasileiou cg, M., Vasiliev cs, A., Vechernin dv, V., Veldhoen bb, M., Velure q, A., Venaruzzo x, M., Vercellin y, E., Vergara Limón b, S., Vernet h, R., Verweij dz, M., Vickovic dh, L., Viesti ab, G., Viinikainen do, J., Vilakazi bj, Z., Villalobos Baillie cu, O., Vinogradov cs, A., Vinogradov dv, L., Vinogradov cr, Y., Virgili ac, T., Viyogi dw, Y. P., Vodopyanov bk, A., Völkl cl, M. A., Voloshin bc, K., Voloshin dz, S. A., Volpe ah, G., von Haller ah, B., Vorobyev dv, I., Vranic cp, D., Vrláková al, J., Vulpescu bo, B., Vyushin cr, A., Wagner q, B., Wagner cp, J., Wagner ak, V., Wang g, M., Wang cl, Y., Watanabe ds, D., Weber dn, M., Wessels ay, J. P., Westerhoff ay, U., Wiechula ag, J., Wikne u, J., Wilde ay, M., Wilk bv, G., Wilkinson cl, J., Williams cx, M. C. S., Windelband cl, B., Winn cl, M., Xiang g, C., Yaldo dz, C. G., Yamaguchi dr, Y., Yang bb, H., Yang g, P., Yang q, S., Yano aq, S., Yasnopolskiy cs, S., Yi co, J., Yin g, Z., Yoo co, I. K., Yushmanov cs, I., Zaccolo by, V., Zach ak, C., Zaman o, A., Zampolli cx, C., Zaporozhets bk, S., Zarochentsev dv, A., Závada be, P., Zaviyalov cr, N., Zbroszczyk dy, H., Zgura bg, I. S., Zhalov cd, M., Zhang g, F., Zhang g, H., Zhang bo, X., Bs, G, Zhangg, Y., Zhaou, C., Zhoug, D., Zhoug, F., Zhoubb, Y., Zhug, H., Zhudf, J., G, Zhug, J., Zhug, X., Zichichil, A., Zimmermann cl, A., Zimmermann ay, M. B., Zinovjev c, G., Zoccarato du, Y., Zynovyev c, M., Zyzak aw, M., Piano, Stefano, Lea, Ramona, Camerini, Paolo, Luparello, Grazia, Margagliotti, Giacomo, Rui, Rinaldo, B., Abelev bt, J., Adam ak, D., Adamová cb, M. M., Aggarwal cf, G., Aglieri Rinella ah, M., Agnello cm, Dd, A., Agostinelli z, N., Agrawal ar, Z., Ahammed dw, N., Ahmad r, A., Ahmad Masoodi r, I., Ahmed o, S. U., Ahn bm, S. A., Ahn bm, I., Aimo cm, S., Aiola eb, M., Ajaz o, A., Akindinov bc, D., Aleksandrov c, B., Alessandro dd, D., Alexandre cu, A., Alici cx, L, A., Alkin c, J., Alme ai, T., Alt am, V., Altini ae, S., Altinpinar q, I., Altsybeev dv, C., Alves Garcia Prado dl, C., Andrei bw, A., Andronic cp, V., Anguelov cl, J., Anielski ay, T., Anticˇic ́ cq, F., Antinori da, P., Antonioli cx, L., Aphecetche df, H., Appelshäuser aw, N., Arbor bp, S., Arcelli z, N., Armesto p, R., Arnaldi dd, T., Aronsson eb, I. C., Arsene u, Cp, M., Arslandok aw, A., Augustinus ah, R., Averbeck cp, T. C., Awes cc, M. D., Azmi r, Ch, M., Bach am, A., Badalà cz, Y. W., Baek an, Bo, S., Bagnasco dd, R., Bailhache aw, V., Bairathi cj, R., Bala ci, A., Baldisseri n, F., Baltasar Dos Santos Pedrosa ah, J., Bán bd, R. C., Baral bf, R., Barbera aa, F., Barile ae, G. G., Barnaföldi ea, L. S., Barnby cu, V., Barret bo, J., Bartke di, M., Basile z, N., Bastid bo, S., Basu dw, B., Bathen ay, G., Batigne df, B., Batyunya bk, P. C., Batzing u, C., Baumann aw, I. G., Bearden by, H., Beck aw, C., Bedda cm, N. K., Behera ar, I., Belikov az, F., Bellini z, R., Bellwied dn, E., Belmont Moreno bi, G., Bencedi ea, S., Beole y, I., Berceanu bw, A., Bercuci bw, Y., Berdnikov cd, D., Berenyi ea, M. E., Berger ck, R. A., Bertens bb, D., Berzano y, L., Betev ah, A., Bhasin ci, A. K., Bhati cf, B., Bhattacharjee ao, J., Bhom d, L., Bianchi y, N., Bianchi bq, C., Bianchin bb, J., Bielcˇík ak, J., Bielcˇíková cb, A., Bilandzic by, S., Bjelogrlic bb, F., Blanco j, D., Blau c, C., Blume aw, F., Bock cl, Bs, A., Bogdanov bu, H., Bøggild by, M., Bogolyubsky de, F. V., Böhmer ck, L., Boldizsár ea, M., Bombara al, J., Book aw, H., Borel n, A., Borissov dz, Co, J., Bornschein am, F., Bossú bj, M., Botje bz, E., Botta y, S., Böttger av, P., Braun Munzinger cp, M., Bregant dl, T., Breitner av, T. A., Broker aw, T. A., Browning cn, M., Broz aj, Ak, E., Bruna dd, G. E., Bruno ae, D., Budnikov cr, H., Buesching aw, S., Bufalino dd, P., Buncic ah, O., Busch cl, Z., Buthelezi bj, D., Caffarri ab, X., Cai g, H., Caines eb, A., Caliva bb, E., Calvo Villar cv, V., Canoa Roman ah, F., Carena ah, W., Carena ah, F., Carminati ah, A., Casanova Díaz bq, J., Castillo Castellanos n, E. A. R., Casula w, V., Catanescu bw, C., Cavicchioli ah, C., Ceballos Sanchez i, J., Cepila ak, P., Cerello dd, B., Chang do, S., Chapeland ah, J. L., Charvet n, S., Chattopadhyay dw, S., Chattopadhyay ct, M., Cherney ce, C., Cheshkov du, B., Cheynis du, V., Chibante Barroso ah, D. D., Chinellato dn, Dm, P., Chochula ah, M., Chojnacki by, S., Choudhury dw, P., Christakoglou bz, C. H., Christensen by, P., Christiansen af, T., Chujo d, S. U., Chung co, C., Cicalo cy, L., Cifarelli l, Z, F., Cindolo cx, J., Cleymans ch, F., Colamaria ae, D., Colella ae, A., Collu w, M., Colocci z, G., Conesa Balbastre bp, Z., Conesa del Valle au, Ah, M. E., Connors eb, Contin x, G., J. G., Contreras k, T. M., Cormier cc, Dz, Y., Corrales Morales y, P., Cortese ad, I., Cortés Maldonado b, M. R., Cosentino b, Dl, F., Costa ah, P., Crochet bo, R., Cruz Albino k, E., Cuautle bh, L., Cunqueiro bq, A., Dainese da, R., Dang g, A., Danu bg, D., Das ct, I., Das au, K., Das ct, S., Das d, A., Dash dm, S., Dash ar, S., De dw, H., Delagrange df, A., Deloff bv, E., Dénes ea, G., D’Erasmo ae, G. O. V., de Barros dl, A., De Caro l, Ac, G., de Cataldo cw, J., de Cuveland am, A., De Falco w, D., De Gruttola ac, N., De Marco dd, S., De Pasquale ac, R., de Rooij bb, M. A., Diaz Corchero j, T., Dietel ay, R., Divià ah, D., Di Bari ae, S., Di Liberto db, A., Di Mauro ah, P., Di Nezza bq, Ø., Djuvsland q, A., Dobrin bb, T., Dobrowolski bv, D., Domenicis Gimenez dl, B., Dönigus aw, O., Dordic u, S., Dørheim ck, A. K., Dubey dw, A., Dubla bb, L., Ducroux du, P., Dupieux bo, A. K., Dutta Majumdar ct, R. J., Ehlers eb, D., Elia cw, H., Engel av, B., Erazmus ah, Df, H. A., Erdal ai, D., Eschweiler am, B., Espagnon au, M., Estienne df, S., Esumi d, D., Evans cu, S., Evdokimov de, G., Eyyubova u, D., Fabris da, J., Faivre bp, D., Falchieri z, A., Fantoni bq, M., Fasel cl, D., Fehlker q, L., Feldkamp ay, D., Felea bg, A., Feliciello dd, G., Feofilov dv, J., Ferencei cb, A., Fernández Téllez b, E. G., Ferreiro p, A., Ferretti y, A., Festanti ab, J., Figiel di, M. A. S., Figueredo dl, Dp, S., Filchagin cr, D., Finogeev ba, F. M., Fionda ae, E. M., Fiore ae, E., Floratos cg, M., Floris ah, S., Foertsch bj, P., Foka cp, S., Fokin c, E., Fragiacomo dc, A., Francescon ab, U., Frankenfeld cp, U., Fuchs ah, C., Furget bp, M., Fusco Girard ac, J. J., Gaardhøje by, M., Gagliardi y, A. M., Gago cv, M., Gallio y, D. R., Gangadharan, P., Ganoti cg, Cc, C., Garabatos cp, E., Garcia Solis m, C., Gargiulo ah, I., Garishvili bt, J., Gerhard am, M., Germain df, A., Gheata ah, M., Gheata bg, B., Ghidini ae, P., Ghosh dw, S. K., Ghosh d, P., Gianotti bq, P., Giubellino ah, E., Gladysz Dziadus di, P., Glässel cl, R., Gomez k, P., González Zamora j, S., Gorbunov am, L., Görlich di, S., Gotovac dh, L. K., Graczykowski dy, R., Grajcarek cl, A., Grelli bb, A., Grigoras ah, C., Grigoras ah, V., Grigoriev bu, A., Grigoryan a, S., Grigoryan bk, B., Grinyov c, N., Grion dc, J. F., Grosse Oetringhaus ah, J. Y., Grossiord du, R., Grosso ah, F., Guber ba, R., Guernane bp, B., Guerzoni z, M., Guilbaud du, K., Gulbrandsen by, H., Gulkanyan a, T., Gunji dr, A., Gupta ci, R., Gupta ci, K. H., Khan o, R., Haake ay, Ø., Haaland q, C., Hadjidakis au, M., Haiduc bg, H., Hamagaki dr, G., Hamar ea, L. D., Hanratty cu, A., Hansen by, J. W., Harris eb, H., Hartmann am, A., Harton m, D., Hatzifotiadou cx, S., Hayashi dr, S. T., Heckel aw, M., Heide ay, H., Helstrup ai, A., Herghelegiu bw, G., Herrera Corral k, B. A., Hess ag, K. F., Hetland ai, B., Hicks eb, B., Hippolyte az, J., Hladky be, P., Hristov ah, M., Huang q, T. J., Humanic, D., Hutter am, D. S., Hwang t, R., Ilkaev cr, I., Ilkiv bv, M., Inaba d, E., Incani w, G. M., Innocenti y, C., Ionita ah, M., Ippolitov c, M., Irfan r, M., Ivanov cp, V., Ivanov cd, O., Ivanytskyi c, A., Jachołkowski aa, P. M., Jacobs b, C., Jahnke dl, H. J., Jang bm, M. A., Janik dy, P. H. S. Y., Jayarathna dn, S., Jena ar, Dn, R. T., Jimenez Bustamante bh, P. G., Jones cu, H., Jung an, A., Jusko cu, S., Kalcher am, P., Kalinak bd, A., Kalweit ah, J., Kamin aw, J. H., Kang ec, V., Kaplin bu, S., Kar dw, A., Karasu Uysal bn, O., Karavichev ba, T., Karavicheva ba, E., Karpechev ba, U., Kebschull av, R., Keidel ed, B., Ketzer ck, M. M., Khan r, P., Khan ct, S. A., Khan dw, A., Khanzadeev cd, Y., Kharlov de, B., Kileng ai, B., Kim ec, D. W., Kim bm, An, D. J., Kim do, J. S., Kim an, M., Kim an, M., Kim ec, S., Kim t, T., Kim ec, S., Kirsch am, I., Kisel am, S., Kiselev bc, A., Kisiel dy, G., Kiss ea, J. L., Klay f, J., Klein cl, C., Klein Bösing ay, A., Kluge ah, M. L., Knichel cp, A. G., Knospe dj, C., Kobdaj ah, Dg, M., Kofarago ah, M. K., Köhler cp, T., Kollegger am, A., Kolojvari dv, V., Kondratiev dv, N., Kondratyeva bu, A., Konevskikh ba, V., Kovalenko dv, M., Kowalski ah, Di, S., Kox bp, G., Koyithatta Meethaleveedu ar, J., Kral do, I., Králik bd, F., Kramer aw, A., Kravcˇáková al, M., Krelina ak, M., Kretz am, M., Krivda cu, Bd, F., Krizek cb, Ap, M., Krus ak, E., Kryshen cd, M., Krzewicki cp, V., Kucˇera cb, Y., Kucheriaev c, T., Kugathasan ah, C., Kuhn az, P. G., Kuijer bz, I., Kulakov aw, J., Kumar ar, P., Kurashvili bv, A., Kurepin ba, A. B., Kurepin ba, A., Kuryakin cr, S., Kushpil cb, V., Kushpil cb, M. J., Kweon cl, At, Y., Kwon ec, P., Ladron de Guevara bh, C., Lagana Fernandes dl, I., Lakomov au, R., Langoy dx, C., Lara av, A., Lardeux df, A., Lattuca y, S. L., La Pointe dd, Bb, P., La Rocca aa, L., Leardini cl, G. R., Lee cu, I., Legrand ah, J., Lehnert aw, R. C., Lemmon ca, M., Lenhardt cp, V., Lenti cw, E., Leogrande bb, M., Leoncino y, I., León Monzón dk, P., Lévai ea, S., Li g, J., Lien dx, R., Lietava cu, S., Lindal u, V., Lindenstruth am, C., Lippmann cp, M. A., Lisa, H. M., Ljunggren af, D. F., Lodato bb, P. I., Loenne q, V. R., Loggins dz, V., Loginov bu, D., Lohner cl, C., Loizides b, X., Lopez bo, E., López Torres i, X. G., Lu cl, P., Luettig aw, M., Lunardon ab, J., Luo g, C., Luzzi ah, R., Ma eb, A., Maevskaya ba, M., Mager ah, D. P., Mahapatra bf, A., Maire cl, Az, M., Malaev cd, I., Maldonado Cervantes bh, L., Malinina bk, D., Mal’Kevich bc, P., Malzacher cp, A., Mamonov cr, L., Manceau dd, V., Manko c, F., Manso bo, V., Manzari ah, Cw, M., Marchisone y, J., Mareš be, A., Margotti cx, A., Marín cp, C., Markert ah, Dj, M., Marquard aw, I., Martashvili dq, N. A., Martin cp, P., Martinengo ah, M. I., Martínez b, G., Martínez García df, J., Martin Blanco df, Y., Martynov c, A., Mas df, S., Masciocchi cp, M., Masera y, A., Masoni cy, L., Massacrier df, A., Mastroserio ae, A., Matyja di, C., Mayer di, J., Mazer dq, R., Mazumder a, M. A., Mazzoni db, F., Meddi v, A., Menchaca Rocha bi, E., Meninno ac, J., Mercado Pérez cl, M., Meres aj, Y., Miake d, K., Mikhaylov bc, Bk, L., Milano ah, J., Milosevic u, A., Mischke bb, A. N., Mishra a, D., Mis ́kowiec cp, C. M., Mitu bg, J., Mlynarz dz, B., Mohanty dw, Bx, L., Molnar az, L., Montaño Zetina k, E., Montes j, M., Morando ab, D. A., Moreira De Godoy dl, S., Moretto ab, A., Morreale do, A., Morsch ah, V., Muccifora bq, E., Mudnic dh, S., Muhuri dw, M., Mukherjee dw, H., Müller ah, M. G., Munhoz dl, S., Murray ch, L., Musa ah, J., Musinsky bd, B. K., Nandi ar, R., Nania cx, E., Nappi cw, C., Nattrass dq, T. K., Nayak dw, S., Nazarenko cr, A., Nedosekin bc, M., Nicassio cp, M., Niculescu bg, B. S., Nielsen by, S., Nikolaev c, S., Nikulin c, V., Nikulin cd, B. S., Nilsen ce, F., Noferini l, Cx, P., Nomokonov bk, G., Nooren bb, A., Nyanin c, J., Nystrand q, H., Oeschler cl, Ax, S., Oh eb, S. K., Oh bl, An, 6, A., Okatan bn, L., Olah ea, J., Oleniacz dy, A. C., Oliveira Da Silva dl, J., Onderwaater cp, C., Oppedisano dd, A., Ortiz Velasquez af, A., Oskarsson af, J., Otwinowski cp, K., Oyama cl, Y., Pachmayer cl, M., Pachr ak, P., Pagano ac, G., Paic ́ bh, F., Painke am, C., Pajares p, S. K., Pal dw, A., Palmeri cz, D., Pant ar, V., Papikyan a, G. S., Pappalardo cz, W. J., Park cp, A., Passfeld ay, D. I., Patalakha de, V., Paticchio cw, B., Paul ct, T., Pawlak dy, T., Peitzmann bb, H., Pereira Da Costa n, E., Pereira De Oliveira Filho dl, D., Peresunko c, C. E., Pérez Lara bz, W., Peryt dy, A., Pesci cx, Y., Pestov e, V., Petrácˇek ak, M., Petran ak, M., Petris bw, M., Petrovici bw, C., Petta aa, M., Pikna aj, P., Pillot df, O., Pinazza ah, L., Pinsky dn, D. B., Piyarathna dn, M., Płoskon ́ b, M., Planinic cq, Dt, J., Pluta dy, S., Pochybova ea, P. L. M., Podesta Lerma dk, M. G., Poghosyan ah, Ce, E. H. O., Pohjoisaho ap, B., Polichtchouk de, N., Poljak cq, A., Pop bw, S., Porteboeuf Houssais bo, J., Porter b, V., Pospisil ak, B., Potukuchi ci, S. K., Prasad d, R., Preghenella cx, F., Prino dd, C. A., Pruneau dz, I., Pshenichnov ba, G., Puddu w, V., Punin cr, J., Putschke dz, H., Qvigstad u, A., Rachevski dc, S., Raha d, J., Rak do, A., Rakotozafindrabe n, L., Ramello ad, R., Raniwala cj, S., Raniwala cj, S. S., Räsänen ap, B. T., Rascanu aw, D., Rathee cf, A. W., Rauf o, V., Razazi w, K. F., Read dq, J. S., Real bp, K., Redlich bv, R. J., Reed eb, A., Rehman q, P., Reichelt aw, M., Reicher bb, F., Reidt cl, R., Renfordt aw, A. R., Reolon bq, A., Reshetin ba, F., Rettig am, J. P., Revol ah, K., Reygers cl, V., Riabov cd, R. A., Ricci br, T., Richert af, M., Richter u, P., Riedler ah, W., Riegler ah, F., Riggi aa, A., Rivetti dd, E., Rocco bb, M., Rodríguez Cahuantzi b, A., Rodriguez Manso bz, K., Røed u, E., Rogochaya bk, S., Rohni ci, D., Rohr am, D., Röhrich q, R., Romita dp, Ca, F., Ronchetti bq, L., Ronflette df, P., Rosnet bo, S., Rossegger ah, A., Rossi ah, F., Roukoutakis cg, A., Roy a, C., Roy az, P., Roy ct, A. J., Rubio Montero j, R., Russo y, E., Ryabinkin c, Y., Ryabov cd, A., Rybicki di, S., Sadovsky de, K., Šafarˇík ah, B., Sahlmuller aw, R., Sahoo a, P. K., Sahu bf, J., Saini dw, C. A., Salgado p, J., Salzwedel, S., Sambyal ci, V., Samsonov cd, X., Sanchez Castro az, Bh, F. J., Sánchez Rodríguez dk, L., Šándor bd, A., Sandoval bi, M., Sano d, G., Santagati aa, D., Sarkar dw, E., Scapparone cx, F., Scarlassara ab, R. P., Scharenberg cn, C., Schiaua bw, R., Schicker cl, C., Schmidt cp, H. R., Schmidt ag, S., Schuchmann aw, J., Schukraft ah, M., Schulc ak, T., Schuster eb, Y., Schutz ah, K., Schwarz cp, K., Schweda cp, G., Scioli z, E., Scomparin dd, P. A., Scott cu, R., Scott dq, G., Segato ab, J. E., Seger ce, I., Selyuzhenkov cp, J., Seo co, E., Serradilla j, Bi, A., Sevcenco bg, A., Shabetai df, G., Shabratova bk, R., Shahoyan ah, A., Shangaraev de, N., Sharma dq, Bf, S., Sharma ci, K., Shigaki aq, K., Shtejer y, Y., Sibiriak c, S., Siddhanta cy, T., Siemiarczuk bv, D., Silvermyr cc, C., Silvestre bp, G., Simatovic dt, R., Singaraju dw, R., Singh ci, S., Singha bx, Dw, V., Singhal dw, B. C., Sinha dw, T., Sinha ct, B., Sitar aj, M., Sitta ad, T. B., Skaali u, K., Skjerdal q, R., Smakal ak, N., Smirnov eb, R. J. M., Snellings bb, C., Søgaard af, R., Soltz bt, J., Song co, M., Song ec, F., Soramel ab, S., Sorensen dq, M., Spacek ak, I., Sputowska di, M., Spyropoulou Stassinaki cg, B. K., Srivastava cn, J., Stachel cl, I., Stan bg, G., Stefanek bv, M., Steinpreis, E., Stenlund af, G., Steyn bj, J. H., Stiller cl, D., Stocco df, M., Stolpovskiy de, P., Strmen aj, A. A. P., Suaide dl, M. A., Subieta Vasquez y, T., Sugitate aq, C., Suire au, M., Suleymanov o, R., Sultanov bc, M., Šumbera cb, T., Susa cq, T. J. M., Symons b, A., Szanto de Toledo dl, I., Szarka aj, A., Szczepankiewicz ah, M., Szymanski dy, J., Takahashi dm, M. A., Tangaro ae, J. D., Tapia Takaki au, A., Tarantola Peloni aw, A., Tarazona Martinez ah, M. G., Tarzila bw, A., Tauro ah, G., Tejeda Muñoz b, A., Telesca ah, C., Terrevoli w, A., Ter Minasyan bu, J., Thäder cp, D., Thomas bb, R., Tieulent du, A. R., Timmins dn, A., Toia da, Aw, H., Torii dr, V., Trubnikov c, W. H., Trzaska do, T., Tsuji dr, A., Tumkin cr, R., Turrisi da, T. S., Tveter u, J., Ulery aw, K., Ullaland q, A., Uras du, G. L., Usai w, M., Vajzer cb, M., Vala bk, L., Valencia Palomo au, S., Vallero y, Cl, P., Vande Vyvre ah, L., Vannucci br, J., Van Der Maarel bb, J. W., Van Hoorne ah, M., van Leeuwen bb, A., Vargas b, R., Varma ar, M., Vasileiou cg, A., Vasiliev c, V., Vechernin dv, M., Veldhoen bb, A., Velure q, M., Venaruzzo x, E., Vercellin y, S., Vergara Limón b, R., Vernet h, M., Verweij dz, L., Vickovic dh, G., Viesti ab, J., Viinikainen do, Z., Vilakazi bj, O., Villalobos Baillie cu, A., Vinogradov c, L., Vinogradov dv, Y., Vinogradov cr, T., Virgili ac, Y. P., Viyogi dw, A., Vodopyanov bk, M. A., Völkl cl, K., Voloshin bc, S. A., Voloshin dz, G., Volpe ah, B., von Haller ah, I., Vorobyev dv, D., Vranic cp, J., Vrláková al, B., Vulpescu bo, A., Vyushin cr, B., Wagner q, J., Wagner cp, V., Wagner ak, M., Wang g, Y., Wang cl, D., Watanabe d, M., Weber dn, J. P., Wessels ay, U., Westerhoff ay, J., Wiechula ag, J., Wikne u, M., Wilde ay, G., Wilk bv, J., Wilkinson cl, M. C. S., Williams cx, B., Windelband cl, M., Winn cl, C., Xiang g, C. G., Yaldo dz, Y., Yamaguchi dr, H., Yang bb, P., Yang g, S., Yang q, S., Yano aq, S., Yasnopolskiy c, J., Yi co, Z., Yin g, I. K., Yoo co, I., Yushmanov c, Zaccolo by, V., C., Zach ak, A., Zaman o, C., Zampolli cx, S., Zaporozhets bk, A., Zarochentsev dv, P., Závada be, N., Zaviyalov cr, H., Zbroszczyk dy, I. S., Zgura bg, M., Zhalov cd, F., Zhang g, H., Zhang g, X., Zhang bo, G, B, Y., Zhangg, C., Zhaou, D., Zhoug, F., Zhoug, Y., Zhoubb, H., Zhug, J., Zhudf, G, J., Zhug, X., Zhug, A., Zichichil, A., Zimmermann cl, M. B., Zimmermann ay, G., Zinovjev c, Y., Zoccarato du, M., Zynovyev c, and M., Zyzak aw
- Subjects
Particle ratios ,ALICE ,High pT ,Nuclear modification factor ,Identified particle production ,Particle ratio ,LHC ,Baryon anomaly - Abstract
Transverse momentum spectra of π±, K± and p(p ̄) up to pT = 20 GeV/c at mid-rapidity in pp, peripheral (60–80%) and central (0–5%) Pb–Pb collisions at √sNN = 2.76 TeV have been measured using the ALICE detector at the Large Hadron Collider. The proton-to-pion and the kaon-to-pion ratios both show a distinct peak at pT ≈ 3 GeV/c in central Pb–Pb collisions. Below the peak, pT < 3 GeV/c, both ratios are in good agreement with hydrodynamical calculations, suggesting that the peak itself is dominantly the result of radial flow rather than anomalous hadronization processes. For pT > 10 GeV/c particle ratios in pp and Pb–Pb collisions are in agreement and the nuclear modification factors for π±, K± and p(p ̄) indicate that, within the systematic and statistical uncertainties, the suppression is the same. This suggests that the chemical composition of leading particles from jets in the medium is similar to that of vacuum jets.
- Published
- 2014
25. Oncolytic Viruses for Tumor Precision Imaging and Radiotherapy.
- Author
-
Wu, Zi J., Tang, Feng R., Ma, Zhao-Wu, Peng, Xiao-Chun, Xiang, Ying, Zhang, Yanling, Kang, Jingbo, Ji, Jiafu, Liu, Xiao Q., Wang, Xian-Wang, Xin, Hong-Wu, and Ren, Bo X.
- Published
- 2018
- Full Text
- View/download PDF
26. Culture-independent analysis of microflora in Gayals (Bos frontalis) feces
- Author
-
Run-chi, G, Zun-xi, H, Chang-fei, W, Bo, X, and Xiao-yan, W
- Subjects
Gayal, culture-independent, fecal, phylogenetic analysis, 16S/18S rDNA - Abstract
Comparative DNA sequence analysis of 16S/18S rRNA genes (rDNA) were undertaken to further our understanding of the make-up of micro-organisms communities in the feces of Gayals. Total DNA wereextracted from the feces of 5 Gayals. Two rDNA libraries (16S/18S rDNA) were constructed. In the 16S rDNA library, phylogenetic and sequence similarity analyses of the resultant 71 clone sequences revealed the presence of 67 operational taxonomic units (OTUs) or phylotypes and defined as having more than 97% of sequence similarity. The sequences were affiliated with the following phyla: Firmicutes (34.3%), Bacteroidetes (6.0%), Proteobacteria (4.5%), and uncultured bacteria (55.2%). A setof 58 sequences were analyzed in the 18S rDNA library, which were classified into 27 OTUs. They were mainly affiliated with the following phyla: Protozoa (25.9%), Basidiomycota (3.7%), Ascomycota (11.1%),and uncultured eukaryotes (59.3%). The sequence analysis indicated that more than half of the species, harbored in Gayals fecal belonged to the not-yet-cultured groups at 90% 16S/18S similarity levels with cultured species. In addition, micro-organisms of Chytridiomycetes was one of the most significant cellulose producing species obtained from the Gayal feces as well.
- Published
- 2012
27. Characterization of 6 Bacillus subtilis -mannanases and their genes
- Author
-
Bo, X, Lei, D, Xiang-hua, T, Jun-jun, L, Yun-juan, Y, Yue-lin, M, and Zunxi, H
- Subjects
mannanase, enzyme characterization, gene cloning.FLT - Abstract
No Abstract
- Published
- 2011
28. Contributors
- Author
-
ALOthman, Z.A., An, J., Batmunkh, M., Biggs, M.J., Bo, X., Chen, P., Chen, T., Cheng, L., Fang, S., Grace, T., Guo, L.-H., Hao, B., He, S., Hou, J., Hu, G., Jian, M.Q., Jiang, K., Kang, L.X., Li, D., Li, N., Li, Q., Liu, T., Lv, T., Ma, P.C., Peng, H., Qin, D., Qiu, H., Shapter, J.G., Shearer, C., Shen, H., Shen, L., Sun, X., Tune, D., Wagberg, T., Wan, B., Wang, F., Wang, L., Wang, X., Wang, Z., Wu, H., Xia, K.L., Xie, H.H., Xue, Y., Yang, J., Yao, Y., Yong, Z.Z., Yu, L., Yuan, W., Yuan, Q., Zhan, Z., Zhang, X., Zhang, X.H., Zhang, Y., Zhang, Y.Y., Zheng, L., and Zhou, M.
- Published
- 2017
- Full Text
- View/download PDF
29. P2X purinoceptors inpostmortem human cerebral arteries. J Cardiovasc Pharmacol. 1998 May;31(5):794-9.PubMed PMID: 9593081
- Author
-
Bo, X, Karoon, P, Nori, Stefania Lucia, Bardini, M, and Burnstock, G.
- Published
- 1998
30. Coexpression of mRNAs forP2X1, P2X2 and P2X4 receptors in rat vascular smooth muscle: an in situhybridization and RT-PCR study. J Vasc Res. 1998 May-Jun;35(3):179-85. PubMedPMID: 9647332
- Author
-
Nori, Stefania Lucia, Fumagalli, L, Bo, X, Bogdanov, Y, and Burnstock, G.
- Published
- 1998
31. Current-transport mechanisms of isotype n-ZnO/n-GaN heterostructures.
- Author
-
Alivov, Ya. I., Bo, X., Fan, Q., Akarca-Biyikli, S., Johnstone, D., Lopatiuk, O., Chernyak, L., Litton, C. W., and Morkoç, H.
- Published
- 2007
- Full Text
- View/download PDF
32. Multi-Layer Model for Stressor Film Deposition.
- Author
-
Loiko, K.V., Adams, V., Tekleab, D., Winstead, B., Bo, X.-Z., Grudowski, P., Goktepeli, S., Filipiak, S., Goolsby, B., Kolagunta, V., and Foisy, M.C.
- Published
- 2006
- Full Text
- View/download PDF
33. 900 – Cortical surface area correlates of STON2 gene Ser307Pro polymorphism in patients with schizophrenia and healthy controls
- Author
-
Bo, X.
- Published
- 2013
- Full Text
- View/download PDF
34. Plasma angiotensin converting enzyme level and permanent atrial fibrillation with mitral valvular disease.
- Author
-
Yongjun Q, Hanzhang S, Tongxing L, Dongmin W, Bo X, Jun M, and Xijun X
- Abstract
Background: Some studies have suggested that angiotensin converting enzyme (ACE) may be associated with permanent atrial fibrillation (AF), but these studies were limited by the absence of structural heart disease in the study group. The aim of this study was to investigate whether ACE may have a significant relationship to permanent AF with mitral valvular diseases. Methods: We studied 184 consecutive patients requiring surgery for valvular disease involving only the mitral valve. On admission to the study, all patients underwent a physical examination, 12-lead electrocardiography, and echocardiography. Plasma ACE was measured in all patients. Patients who had permanent AF formed the AF group, and those who had sinus rhythm (SR) comprised the SR group. In the AF group, patients were further divided into 2 subgroups according to type of mitral valvular disease. Patients with mitral stenosis and patients with mitral regurgitation formed the MS-AF group and the MR-AF groups, respectively. AF was diagnosed in 47.83% (88/184) of patients with lone mitral valvular disease. Patients who had AF were older (by 6 years) than patients in sinus rhythm, and more often had a history of stroke. Patients with mitral stenosis were more likely to have AF. Results: The plasma level of ACE was significantly higher in the AF group than in the SR group (72.60 ± 22.03 versus 56.40 ± 17.96, P<0.05). AF correlated significantly with the level of ACE (r=0.39), age (r=0.28), and left atrial dimension (LAD) (r=0.26). Level of ACE correlated with LAD (r=0.32). Notably, in the AF group, different types of mitral valvular disease had different levels of ACE. The ACE level in the mitral stenosis group was higher than in the mitral regurgitation group (82.92 ± 18.75 versus 66.25 ± 21.10, P<0.05). Patients with mitral stenosis more frequently had a history of stroke than did patients with mitral regurgitation. Conclusion: We validated and extended the hypothesis that increased ACE level predicts an increased risk of AF in mitral valvular diseases, especially in patients with mitral stenosis. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
35. Overview of Kidney and Urine Proteome Databases.
- Author
-
Yoshida, Y., Miyamoto, M., Bo, X., Yaoita, E., and Yamamoto, T.
- Published
- 2008
- Full Text
- View/download PDF
36. HBx protein of hepatitis B virus (HBV) can form complex with mitochondrial HSP60 and HSP70.
- Author
-
Zhang, S. M., Sun, D. C., Lou, S., Bo, X. C., Lu, Z., Qian, X. H., and Wang, S. Q.
- Subjects
HEPATITIS B virus ,HEPATITIS viruses ,HEPATITIS B ,HEAT shock proteins ,MITOCHONDRIA - Abstract
HBx, a transcriptional transactivating protein of hepatitis B virus (HBV), is required for viral infection and has been implicated in virus-mediated liver oncogenesis. However, the molecular mechanism for its influence on cell remains largely unknown. It was proved that HBx need the help of host cell proteins to exert its function by binding to them. During purifying of GSTX (fusion protein of GST and HBx) expressed in E. coli, we found that it can bind specifically with GrpE (HSP60) and DnaK (HSP70) of E. coli while GST cannot. Using GST pull-down, two-dimensional gel electrophoresis and mass spectrum, we found that GSTX can also bind to human mitochondrial HSP60 and HSP70, which are homologues of GrpE and DnaK. These interactions between HBx and mitochondrial HSP60 and HSP70 are supported by the result of co-immunoprecipitation experiment. It means that HBx can form complex with E. coli and human HSP60 and HSP70. The implication of HBx, HSP60 and HSP70 complex in molecular mechanism of virus infection is discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
37. Creep-induced phase transformations in a Ti–Al alloy.
- Author
-
Y.-W.Kim, Bo X.-W.
- Subjects
- *
MATHEMATICAL transformations , *ALLOYS - Abstract
The alloy Ti-46.5 at.% Al-2 at.% Cr-3 at.% Nb-0.2 at.% W with a fully lamellar microstructure was subjected to creep deformation at 1073 K and 270 MPa. After creep deformation, fine lamellae consisting of γ and α[sub 2 ]laths and β precipitates were observed, which do not exist in the undeformed material, and these observations are explained by α[sub 2] → γ and α[sub 2 ]→ β-phase transformations. To understand the mechanisms of phase transformations, an overall investigation has been made by combining transmission electron microscopy, high-resolution electron microscopy, energy-dispersive spectroscopy and the fast Fourier transform technique. It was found that the two kinds of phase transformation have a close relationship but proceed by different mechanisms. The α[sub 2] → γ-phase transformation is a kind of stressinduced phase transformation, while the α2 → β-phase transformation is due to the segregation of the elements Cr and W. [ABSTRACT FROM AUTHOR]
- Published
- 2002
38. Characterization and autoradiographic localization of [3H]α,β-methylene adenosine 5'-triphosphate binding sites in human urinary bladder.
- Author
-
BO, X. and BURNSTOCK, G.
- Abstract
Objectives To characterize [
3 H]α,β-methylene adenosine 5′-triphosphate ([3 H]α,β-MeATP, a radioligand for P2X -purinoceptors) binding sites in the washed homogenates and membrane preparations of human urinary bladder and, using autoradiography, to localize [3 H]α,β-MeATP binding sites in human bladder. Materials and methods Specimens were obtained from the fundus of the urinary bladder of male patients aged 56-79 years. The washed homogenates or membrane preparations of the bladder specimens were incubated with [3 H]α,β-MeATP and the bound and free radioligand separated by filtration. For autoradiography, cryostat sections were incubated with 10 nM [3 H]α,β-MeATP, washed, dried and exposed for 2 weeks to emulsion-coated coverslips. In both experiments, 100 μ mβ,γ-methylene ATP was used to determine non-specific binding. Results Six of 16 specimens in the binding assay and three of seven specimens in the localization study showed specific [3 H]α,β-MeATP binding. The binding process was saturable and the specific binding sites were composed of a high-and low-affinity component. The specific binding to membrane preparations was reduced in the presence of Mg2+ in the incubation medium. Competitive displacement experiments showed that the order of potency of the unlabelled ligands to displace the [3 H]α,β-MeATP binding was α,β-methylene ATP < β,γ-methylene ATP < suramin < 2-methylthio ATP < ATP > ADP ≫ adenosine, which indicates that the binding sites are, or are linked to, P2X -purinoceptors. Autoradiography showed that the specific [3 H]α,β-MeATP binding sites were located only over the smooth muscle of the bladder. Conclusions The results suggest that P2X -purinoceptors exist in human urinary bladder, although at a lower density than reported for rodent urinary bladder. [ABSTRACT FROM AUTHOR]- Published
- 1995
- Full Text
- View/download PDF
39. Pentacene-carbon nanotubes: Semiconducting assemblies for thin-film transistor applications.
- Author
-
Bo, X.-Z., Tassi, N. G., Lee, C. Y., Strano, M. S., Nuckolls, C., and Blanchet, Graciela B.
- Subjects
- *
PENTACENE , *NANOTUBES , *SEMICONDUCTORS , *TRANSISTORS , *FERROELECTRIC thin films , *SOLID state electronics , *SOLID state physics - Abstract
We demonstrate an alternative path for achieving high-transconductance organic transistors by assembling bilayers of pentacene onto random arrays of single-walled carbon nanotubes. We show here that, by varying the connectivity of the underlying nanotube network, the channel length of a thin-film transistor can be reduced by nearly two orders of magnitude—thus, enabling the increase of the device transconductance without reduction the on/off ratio. These field-induced percolating networks enable assembling high-transconductance transistors that, with relatively large source drain distances, can be manufactured with available commercial printing techniques. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
40. Carbon nanotubes-semiconductor networks for organic electronics: The pickup stick transistor.
- Author
-
Bo, X.-Z., Lee, C. Y., Strano, M. S., Goldfinger, M., Nuckolls, C., and Blanchet, Graciela B.
- Subjects
- *
TRANSISTORS , *ELECTRONICS , *SEMICONDUCTORS , *NANOTUBES , *PERCOLATION theory , *CARBON - Abstract
We demonstrate an alternative path for achieving high transconductance organic transistors in spite of relatively large source to drain distances. The improvement of the electronic characteristic of such a scheme is equivalent to a 60-fold increase in mobility of the underlying organic semiconductor. The method is based on percolating networks, which we create from a dispersion of individual single-wall carbon nanotubes and narrow ropes within an organic semiconducting host. The majority of current paths between source and drain follow the metallic nanotubes but require a short, switchable semiconducting link to complete the circuit. With these nanotube-semiconducting composites we achieve effectively a 60× reduction in source to drain distance, which is equivalent to a 60-fold increase of the “effective” mobility of the starting semiconducting material with a minor decrease of the on/off current ratio. These field-induced percolating networks allow for the fabrication of high-transconductance transistors having relatively large source to drain distances that can be manufactured inexpensively by commercially available printing techniques. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
41. Control two-link flexible manipulators using controlled Lagrangian method.
- Author
-
Bo, X. and Hayakawa, Y.
- Published
- 2004
42. Oesophagogastric intramural implantation anastomosis after oesophagectomy.
- Author
-
Cheng, C. S., Zhang, M. K., Zhang, J. L., Wang, F. Z., Bo, X. S., Cheng, Y. L., and Cheng, Y. Y.
- Published
- 1992
- Full Text
- View/download PDF
43. Transplanted Schwann cells engineered to over-express polysialic acid promote regenerative axonal outgrowth of purkinje cells in L1/GAP-43 double transgenic mice
- Author
-
Zhang, Y., Zhang, X., Wu, D., Yeh, J., Richardson, P., and Bo, X.
- Published
- 2006
- Full Text
- View/download PDF
44. Design and pharmacological characterization of selective P2-purinoceptor antagonists
- Author
-
Lambrecht, G., Ardanuy, U., Bäumert, H.G., Bo, X., Hoyle, C.H.V., Nickel, P., Pfaff, O., Ralevic, V., Windscheif, U., Ziganshin, A.U., Ziyal, R., Mutschler, E., and Burnstock, G.
- Published
- 1996
- Full Text
- View/download PDF
45. Differential antibody responses in sows and finishing pigs naturally infected with African swine fever virus under field conditions.
- Author
-
Luong, Hung Q., Lai, Huong TL., Do, Luc D., Ha, Bo X., Nguyen, Giap V., and Vu, Hiep LX.
- Subjects
- *
AFRICAN swine fever , *AFRICAN swine fever virus , *ANTIBODY formation , *SWINE , *SOWS , *HUMORAL immunity - Abstract
• Antibody responses of pigs surviving a natural infection with ASFV under field conditions are described. • Differential antibody responses are observed between sows and finishing pigs. • Antibodies against p32, p54 and pp62 are detected in most pigs surviving a natural ASFV-infection. • Antibodies against C-type lectin and CD2v are mainly detected in sows but rarely in finishing pigs. Antibody profile of pigs naturally infected with a virulent African swine fever virus (ASFV) strain under field conditions was studied. Twenty-three serum samples were collected from pigs surviving a natural ASFV infection: 17 samples from finishing pigs (∼7 months old) and 6 samples from sows (between 12 and 36 months old). Additionally, 24 serum samples were collected from ASFV-naïve pigs to serve as negative controls. All sera from ASFV-surviving pigs tested positive while all sera from control pigs tested negative by two different commercial ELISA kits. Antibody reactivity of each serum sample was simultaneously measured against six selected ASFV antigens including p12, p32, p54, pp62, C-type lectin and CD2v. All ASFV-surviving pigs had antibody against p32, p54 and pp62 while 91.3% surviving pigs had antibody against p12. Only small portions of ASFV-surviving pigs exhibited antibodies against C-type lectin (34.8%) and CD2v (26.1%). While antibodies against p12, p32, p54 and pp62 were similarly detected in both finishing pigs and sows, antibodies against C-type lectin and CD2v were mainly detected in sows but not in finishing pigs. These results suggest a differential humoral immune response to ASFV infection in sows and finishing pigs. Further studies are needed to better understand the nature of immune responses to ASFV infection in different pig populations. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
46. Clinical picture: herpes simplex encephalitis.
- Author
-
Hu Z, Yang Q, Bo X, and Li J
- Published
- 2003
47. Distribution of [ 3H]α, β-Methylene ATP Binding Sites in Pulmonary Blood Vessels of Different Species
- Author
-
Zhao, M., Bo, X., and Burnstock, G.
- Published
- 1996
- Full Text
- View/download PDF
48. Mapping pesticide residues in soil for China: Characteristics and risks.
- Author
-
Chen S, Bo X, and Xu Z
- Subjects
- China, Risk Assessment, Humans, Environmental Monitoring, Soil chemistry, Hydrocarbons, Chlorinated analysis, Pesticide Residues analysis, Soil Pollutants analysis
- Abstract
The widespread application of pesticides in China has led to the accumulation of residues in soil. However, few regional studies have fully elucidated the characteristics of pesticide residues in soil (PRS) and the associated risks to the ecosystem and human health on a national level. Therefore, this study aims to compile a dataset on PRS in China from 2006 to 2020 and analyze the interactions and impacts between PRS and the environment. The average concentration of PRS in China was 243.96 μg/kg which was lower than the levels reported in Euro-Americans and other nations. This study revealed PRS in China predominantly originates from organochlorine pesticide residues, with DDTs and HCHs being significant contributors. Despite the high intensity of pesticide application in the Southeast China, PRS concentrations were comparable to those in the Northeast, due to environmental factors that favor pesticide degradation in the Southeast. Both legacy and in-use pesticides were transported by surface runoff or air current, resulting in their accumulation in soil of the lower Yangtze River basin or the piedmont soil of Qinling Mountains, respectively. The average soil environment carrying capacity of PRS in China was -69.5 kg. The ecological risk contributed by PRS in China was mainly at a negligible level. Carcinogenic risks of PRS to adults (4.6 ×10
-4 ) and children (6 ×10-4 ) exceeded the tolerable thresholds (10-5 ) by a small margin., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
49. Chloramphenicol alleviates 5-fluorouracil-induced cellular senescence through activation of autophagy.
- Author
-
Bai S, Zhao Q, Jia H, He F, and Wang X
- Subjects
- Humans, Signal Transduction drug effects, Cellular Senescence drug effects, Autophagy drug effects, Fluorouracil pharmacology, Chloramphenicol pharmacology, Human Umbilical Vein Endothelial Cells drug effects, Human Umbilical Vein Endothelial Cells metabolism, TOR Serine-Threonine Kinases metabolism
- Abstract
5-Fluorouracil (5-FU) is a first-line treatment for colorectal cancer, but side effects such as severe diarrhea are common in clinical use and have been linked to its induction of normal cell senescence. Chloramphenicol (CAP) is an antibiotic commonly used to treat typhoid or anaerobic infections, but its senescence-related aspects have not been thoroughly investigated. Here, we used 5-FU to induce senescence in human umbilical vein endothelial cells (HUVECs) and investigated the relationship between CAP and cellular senescence at the cellular level. In a model of cellular senescence induced by 5-FU treatment, we discovered that CAP treatment reversed the rise in the percentage of senescence-associated galactosidase (SA-β-gal)-positive cells and decreased the expression of senescence-associated proteins (p16), senescence-associated genes (p21), and senescence-associated secretory phenotypes (SASPs: IL-6, TNF-α). In addition, CAP subsequently restored the autophagic process inhibited by 5-FU and upregulated the levels of autophagy-related proteins. Mechanistically, we found that CAP restored autophagic flux by inhibiting the mTOR pathway, which in turn alleviated FU-induced cellular senescence. Our findings suggest that CAP may help prevent cellular senescence and restore autophagy, opening up new possibilities and approaches for the clinical management of colorectal cancer., Competing Interests: The authors declare that they do not have any commercial or associative interest that represents a conflict of interest in connection with the work submitted.
- Published
- 2024
- Full Text
- View/download PDF
50. An interpretable artificial intelligence framework for designing synthetic lethality-based anti-cancer combination therapies.
- Author
-
Wang J, Wen Y, Zhang Y, Wang Z, Jiang Y, Dai C, Wu L, Leng D, He S, and Bo X
- Subjects
- Humans, Animals, Mice, Cell Line, Tumor, Antineoplastic Combined Chemotherapy Protocols pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Agents pharmacology, Antineoplastic Agents therapeutic use, Artificial Intelligence, Synthetic Lethal Mutations, Neoplasms drug therapy, Neoplasms genetics
- Abstract
Introduction: Synthetic lethality (SL) provides an opportunity to leverage different genetic interactions when designing synergistic combination therapies. To further explore SL-based combination therapies for cancer treatment, it is important to identify and mechanistically characterize more SL interactions. Artificial intelligence (AI) methods have recently been proposed for SL prediction, but the results of these models are often not interpretable such that deriving the underlying mechanism can be challenging., Objectives: This study aims to develop an interpretable AI framework for SL prediction and subsequently utilize it to design SL-based synergistic combination therapies., Methods: We propose a knowledge and data dual-driven AI framework for SL prediction (KDDSL). Specifically, we use gene knowledge related to the SL mechanism to guide the construction of the model and develop a method to identify the most relevant gene knowledge for the predicted results., Results: Experimental and literature-based validation confirmed a good balance between predictive and interpretable ability when using KDDSL. Moreover, we demonstrated that KDDSL could help to discover promising drug combinations and clarify associated biological processes, such as the combination of MDM2 and CDK9 inhibitors, which exhibited significant anti-cancer effects in vitro and in vivo., Conclusion: These data underscore the potential of KDDSL to guide SL-based combination therapy design. There is a need for biomedicine-focused AI strategies to combine rational biological knowledge with developed models., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Production and hosting by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.